eIF4B Inhibitors are a class of compounds that target the eukaryotic initiation factor 4B (eIF4B), a critical component of the translation initiation machinery in eukaryotic cells. eIF4B plays a key role in facilitating the recruitment of ribosomes to messenger RNA (mRNA), a process that is essential for the synthesis of proteins. Specifically, eIF4B enhances the helicase activity of eIF4A, another initiation factor, which unwinds secondary structures in the 5' untranslated region (UTR) of mRNA. This unwinding is necessary for the small ribosomal subunit to scan the mRNA and locate the start codon, thereby initiating translation. Inhibitors of eIF4B disrupt this process, potentially leading to a reduction in global protein synthesis, as well as selective effects on the translation of specific mRNAs that are particularly dependent on eIF4B activity.
Research into eIF4B Inhibitors is valuable for understanding the regulation of translation, a fundamental process that controls gene expression at the post-transcriptional level. By inhibiting eIF4B, scientists can investigate the effects on mRNA translation, especially those mRNAs with complex secondary structures in their 5' UTRs, which are more reliant on eIF4B for efficient translation. This can provide insights into how cells control the synthesis of proteins in response to various stimuli and conditions, such as stress, nutrient availability, and signaling pathways. Additionally, eIF4B is known to interact with other components of the translation initiation complex, including eIF3 and the cap-binding protein eIF4E, so its inhibition may shed light on the broader network of interactions that regulate translation initiation. Understanding these interactions is crucial for unraveling the complexities of translational control and its impact on cellular function, growth, and adaptation. Researchers can use eIF4B Inhibitors as tools to dissect these processes, thereby contributing to a deeper knowledge of how cells regulate protein production in both normal and altered states.
Siehe auch...
Artikel 11 von 16 von insgesamt 16
Anzeigen:
| Produkt | CAS # | Katalog # | Menge | Preis | Referenzen | Bewertung |
|---|---|---|---|---|---|---|
Doxorubicin | 23214-92-8 | sc-280681 sc-280681A | 1 mg 5 mg | $173.00 $418.00 | 43 | |
DNA-Schäden durch Doxorubicin können dazu führen, dass die Zelle der DNA-Reparatur Vorrang vor regulären Funktionen einräumt, wodurch möglicherweise die RNAi-Maschinerie unterdrückt und die eIF2C2-Spiegel gesenkt werden. | ||||||
Camptothecin | 7689-03-4 | sc-200871 sc-200871A sc-200871B | 50 mg 250 mg 100 mg | $57.00 $182.00 $92.00 | 21 | |
Die Hemmung der Topoisomerase I durch Camptothecin kann zu DNA-Schäden führen, was wiederum dazu führen kann, dass RNAi-Prozesse weniger stark in den Fokus rücken und die eIF2C2-Expression sinkt. | ||||||
Geldanamycin | 30562-34-6 | sc-200617B sc-200617C sc-200617 sc-200617A | 100 µg 500 µg 1 mg 5 mg | $38.00 $58.00 $102.00 $202.00 | 8 | |
Durch die Hemmung von Hsp90 kann Geldanamycin Proteine destabilisieren, die mit RNAi in Verbindung stehen, was zu einer Abnahme der eIF2C2-Stabilität oder -Synthese führen könnte. | ||||||
Silvestrol | 697235-38-4 | sc-507504 | 1 mg | $920.00 | ||
Ein natürlicher Wirkstoff, der aus der Pflanze Aglaia foveolata isoliert wurde und für seine starke Hemmung von EIF4AI bekannt ist. | ||||||
Rocaglamide | 84573-16-0 | sc-203241 sc-203241A sc-203241B sc-203241C sc-203241D | 100 µg 1 mg 5 mg 10 mg 25 mg | $270.00 $465.00 $1607.00 $2448.00 $5239.00 | 4 | |
Ein weiterer natürlicher Wirkstoff, der in mehreren Pflanzen, wie z. B. der Gattung Aglaia, vorkommt und eine starke EIF4AI-hemmende Wirkung hat. | ||||||
4E1RCat | 328998-25-0 | sc-361085 sc-361085A | 10 mg 50 mg | $189.00 $797.00 | ||
Ein synthetischer EIF4AI-Hemmer, der den eIF4F-Komplex stören und dadurch die cap-abhängige Translation hemmen soll. | ||||||